Eumycetoma (Fungal Mycetoma) Medication
- Author: George Turiansky, MD; Chief Editor: Dirk M Elston, MD more...
The use of various antifungal agents in the treatment of eumycetoma has been reported. Imidazole antifungal agents appear to be the agents of choice. Of the azole group of antifungal agents, ketoconazole appears to be antifungal agent of choice, although isolated reports of successful treatment with itraconazole exist.
Reportedly, imidazole antifungal agents are variably effective in the treatment of eumycetoma when they are used alone or in conjunction with surgical therapy.
Ketoconazole is a synthetic imidazole antifungal agent. It is a broad-spectrum agent known to be a potent inhibitor of the cytochrome P-450 3A4 enzyme system in vitro. Inhibition of this system impairs the synthesis of ergosterol, a vital component of fungal cell membranes.
Itraconazole is a triazole antifungal agent known to be a potent inhibitor of the cytochrome P-450–dependent synthesis of ergosterol in vitro. It slows fungal cell growth by inhibiting cytochrome P-450–dependent synthesis of ergosterol, a vital component of fungal cell membranes.
Carter HV. On a new and striking form of fungus disease principally affecting the foot and prevailing endemically in many parts of India. Transactions of the Medical and Physical Society of Bombay. 1860. 6:104-42.
Carter HV. On mycetoma or the fungus disease of India. London, England: J & A Churchill; 1874.
Green WO Jr, Adams TE. Mycetoma in the United States; a review and report of seven additional cases. Am J Clin Pathol. 1964 Jul. 42:75-91. [Medline].
Abbott P. Mycetoma in the Sudan. Trans R Soc Trop Med Hyg. 1956 Jan. 50(1):11-24; discussion, 24-30. [Medline].
Werlinger KD, Yen Moore A. Eumycotic mycetoma caused by Cladophialophora bantiana in a patient with systemic lupus erythematosus. J Am Acad Dermatol. 2005 May. 52(5 Suppl 1):S114-7. [Medline].
Turiansky GW, Benson PM, Sperling LC, Sau P, Salkin IF, McGinnis MR, et al. Phialophora verrucosa: a new cause of mycetoma. J Am Acad Dermatol. 1995 Feb. 32(2 Pt 2):311-5. [Medline].
Mathuram Thiyagarajan U, Bagul A, Nicholson ML. A nodulo-cystic eumycetoma caused by Pyrenochaeta romeroi in a renal transplant recipient: A case report. J Med Case Reports. 2011 Sep 14. 5(1):460. [Medline]. [Full Text].
Ahmed AO, Desplaces N, Leonard P, Goldstein F, De Hoog S, Verbrugh H, et al. Molecular detection and identification of agents of eumycetoma: detailed report of two cases. J Clin Microbiol. 2003 Dec. 41(12):5813-6. [Medline].
Hemalata M, Prasad S, Venkatesh K, Niveditha SR, Kumar SA. Cytological diagnosis of actinomycosis and eumycetoma: a report of two cases. Diagn Cytopathol. 2010 Dec. 38(12):918-20. [Medline].
Gabhane SK, Gangane N, Anshu. Cytodiagnosis of eumycotic mycetoma: a case report. Acta Cytol. 2008 May-Jun. 52(3):354-6. [Medline].
Ahmed M, Sureka J, Chacko G, Eapen A. MRI findings in cranial eumycetoma. Indian J Radiol Imaging. 2011 Oct. 21(4):261-3. [Medline].
Mahgoub ES, Gumaa SA. Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg. 1984. 78(3):376-9. [Medline].
Degavre B, Joujoux JM, Dandurand M, Guillot B. First report of mycetoma caused by Arthrographis kalrae: successful treatment with itraconazole. J Am Acad Dermatol. 1997 Aug. 37(2 Pt 2):318-20. [Medline].
Lee MW, Kim JC, Choi JS, Kim KH, Greer DL. Mycetoma caused by Acremonium falciforme: successful treatment with itraconazole. J Am Acad Dermatol. 1995 May. 32(5 Pt 2):897-900. [Medline].
Lacroix C, de Kerviler E, Morel P, Derouin F, Feuilhade de Chavin M. Madurella mycetomatis mycetoma treated successfully with oral voriconazole. Br J Dermatol. 2005 May. 152(5):1067-8. [Medline].
N'diaye B, Dieng MT, Perez A, Stockmeyer M, Bakshi R. Clinical efficacy and safety of oral terbinafine in fungal mycetoma. Int J Dermatol. 2006 Feb. 45(2):154-7. [Medline].
Diaz M, Negroni R, Montero-Gei F, Castro LG, Sampaio SA, Borelli D, et al. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group. Clin Infect Dis. 1992 Mar. 14 Suppl 1:S68-76. [Medline].